目前推使用revumenib治疗复发的NPM1-突变和KMT2A重组的AML,FDA将在2025年10月25日之前作出决定. Revumenib is now recommended for relapsed NPM1-mutated and KMT2A-rearranged AML, pending FDA decision by Oct. 25, 2025.

Revumenib作为Revuforj市场销售,根据AUGMINT-101试验的积极结果,被添加到NCCN关于治疗复发性或复发性国家预防机制1经调整的急性类流质白血病的准则中。 Revumenib, marketed as Revuforj, has been added to the NCCN Guidelines for treating relapsed or refractory NPM1-mutated acute myeloid leukemia, based on positive results from the AUGMENT-101 trial. 还建议对使用KMT2A重新安排的R/R急性白血病进行急性白血病治疗。 It is also recommended for R/R acute leukemia with KMT2A rearrangements. 这种药物是一种口服的脑膜抑制剂,已被批准用于KMT2A转位患者,并正在FDA对NPM1-突变AML进行优先审查,预计将于2025年10月25日作出决定. The drug, an oral menin inhibitor, is approved for patients with KMT2A translocations and is under FDA Priority Review for NPM1-mutated AML, with a decision expected by October 25, 2025.